Detalhe da pesquisa
1.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Proc Natl Acad Sci U S A
; 113(43): 12238-12243, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27791010
2.
7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet.
Br J Nutr
; 120(7): 751-762, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30105962
3.
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Gynecol Oncol
; 144(1): 146-152, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27894751
4.
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Br J Cancer
; 115(3): 303-11, 2016 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27351214
5.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Am J Obstet Gynecol
; 214(1): 99.e1-8, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272866
6.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br J Cancer
; 113(7): 1020-6, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325104
7.
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Tumour Biol
; 36(7): 5505-13, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25669172
8.
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Gynecol Oncol
; 138(1): 11-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25931171
9.
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
Gynecol Oncol
; 139(1): 112-7, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260909
10.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br J Cancer
; 113(11): 1641, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26625219
11.
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Clin Cancer Res
; 24(19): 4845-4853, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941483
12.
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Clin Cancer Res
; 23(19): 5836-5845, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28679774
13.
Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.
Mol Cancer Ther
; 16(2): 323-333, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27956521
14.
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Mol Cancer Ther
; 15(8): 1900-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27256376
15.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
J Exp Clin Cancer Res
; 34: 123, 2015 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26474755
16.
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Mol Cancer Ther
; 14(11): 2519-26, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26333383